Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $801.00 by Analysts at Truist Financial

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target dropped by stock analysts at Truist Financial from $818.00 to $801.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s target price indicates a potential upside of 4.36% from the company’s current price.

A number of other equities research analysts have also issued reports on the company. Cantor Fitzgerald lifted their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. BMO Capital Markets lifted their price objective on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and increased their target price for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, Wells Fargo & Company boosted their price target on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $804.70.

Regeneron Pharmaceuticals Stock Up 2.4%

Shares of NASDAQ:REGN traded up $18.27 during midday trading on Tuesday, reaching $767.56. 88,852 shares of the company were exchanged, compared to its average volume of 745,275. The firm has a market cap of $81.15 billion, a PE ratio of 18.51, a P/E/G ratio of 1.98 and a beta of 0.40. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The stock has a fifty day simple moving average of $765.00 and a two-hundred day simple moving average of $709.34. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $12.07 EPS. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares of the company’s stock, valued at $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 5,274 shares of company stock worth $4,142,738. Corporate insiders own 7.02% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Insigneo Advisory Services LLC grew its stake in Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after acquiring an additional 13 shares during the period. Guardian Wealth Advisors LLC NC lifted its stake in shares of Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 14 shares in the last quarter. TD Private Client Wealth LLC increased its position in shares of Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 15 shares in the last quarter. MCF Advisors LLC lifted its position in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 15 shares in the last quarter. Finally, Rexford Capital Inc. boosted its stake in Regeneron Pharmaceuticals by 5.5% during the 4th quarter. Rexford Capital Inc. now owns 288 shares of the biopharmaceutical company’s stock valued at $222,000 after purchasing an additional 15 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.